Business
from24/7 Wall St.
5 days agoWall Street Thinks These 4 Biotech Stocks Will Double--At Least--This Year
Wall Street analysts assign unanimous or near-unanimous Buy ratings to four clinical-stage biotech companies, implying potential gains up to 384% driven by late-stage pipelines and upcoming catalysts.